Rare diseases
Investigational molecules
Locations
Calcium gluconate is a calcium salt used as a mineral supplement. It is classified under the ATC code A12AA03 as a calcium supplement.[2] The substance is of chemical origin and is an authorised medicine.[1] It is available under product names including calcium gluconate and calcium carbonate, and in one product record it is part of a fixed combination.[2] In the two trials listed in the registry, calcium gluconate appears as an auxiliary treatment, meaning it supports the study but is not the medicine being tested.[2][1]
Calcium gluconate provides calcium, a mineral the body needs for bones, muscles, nerves and blood clotting. When given as an infusion, it can raise the level of calcium in the blood. The South East London Joint Medicines Formulary lists a 10% calcium gluconate injection containing 8.4 mg of elemental calcium per millilitre, and notes a June 2023 MHRA Drug Safety Update on the potential risk of underdosing with calcium gluconate in severe hyperkalaemia.[4] The dm+d browser records a 10% solution for infusion with a strength of 100 mg calcium gluconate per 1 ml, for intravenous or intramuscular use.[3]
Calcium gluconate is given by mouth as tablets or effervescent tablets, and by infusion into a vein.[2] The formulary lists calcium gluconate effervescent tablets containing 89 mg of elemental calcium per tablet and a 10% injection containing 8.4 mg of elemental calcium per millilitre.[4] The dm+d browser records a 10% solution for infusion in 100 ml vials, for intravenous or intramuscular administration.[3]
Two registered trials list calcium gluconate as an auxiliary treatment. Neither trial studies calcium gluconate itself; both investigate the weight-loss medicines AZD9550 and AZD6234 in people with obesity or overweight.[2][1]
The first trial (NCT06862791) is a Phase 2 study that enrolled 360 participants and is completed. It compared AZD9550 and AZD6234 in combination against placebo and against each drug alone. The main measures were the percent change in body weight from baseline after 36 weeks of treatment and the proportion of participants achieving at least 5% weight loss.[2]
The second trial (2023-504215-32-00) is a Phase 1 study that enrolled 176 participants and is completed. It assessed the safety, tolerability, pharmacokinetics (how the body absorbs, distributes and clears the drugs) and pharmacodynamics (the drugs' effects on the body) of AZD9550 alone and in combination with AZD6234 in people with overweight or obesity, with or without type 2 diabetes. The main measures included adverse events, serious adverse events, vital signs, ECG, laboratory tests and pharmacokinetic parameters such as how much of the drug stays in the blood over time (AUC) and the highest blood concentration (Cmax).[1]
In both trials, calcium gluconate was given by infusion as a supporting treatment; the registry also lists calcium carbonate and calcium citrate by mouth in the first trial.[2][1]
The formulary source notes a June 2023 MHRA Drug Safety Update on the potential risk of underdosing with calcium gluconate in severe hyperkalaemia, which is a safety concern rather than a side effect.[4] The provided sources do not list specific side effects of calcium gluconate.
Each condition opens its own overview and trial list
Recruiting trials first
Tell us about your condition – we search every trial in Europe and connect you with the right site.
